Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) elected Ye Xiaoping as chairman and appointed Yang Chengcheng as chief financial officer, effective Tuesday, according to a same-day Hong Kong bourse filing.
The clinical trial services provider also appointed Peng Yifei as chief operating officer and Wu Hao as co-president.
COSCO Shipping Energy Transportation (HKG:1138, SHA:600026) has awarded a 6.45 billion yuan contract to Jiangnan Shipyard for the construction of four LNG vessels, according to a Tuesday filing with the Hong Kong bourse.The company is seeking four LNG carriers, each with a guaranteed cargo capacity of at least 175,000 cubic metres and a deadweight of approximately 80,800 metric tons at design draught, each.Each vessel will cost about 1.61 billion yuan and COSCO Shipping said it would settle payment in five installments.The vessels are scheduled for delivery between 2029 and 2030, and will help "reinforce and expand" the shipping capacity of the company's LNG fleet, COSCO Shipping said.
Far East Consortium International's (HKG:0035) indirect wholly-owned subsidiary CEL agreed to sell an office, a hotel, and a town hall property in the UK to New York- and Singapore-listed AMTD IDEA Group (SGX:HKB), according to a Wednesday Hong Kong bourse filing.The total consideration for the transactions was revised to about 59.5 million pounds sterling from 65.2 million pounds sterling.The office property is valued at about 12.3 million pounds sterling, while the consideration for the Town Hall and Hotel transactions remains unchanged at 24.5 million pounds sterling and 22.7 million pounds sterling, respectively, which includes repayment of the hotel loan.CEL has guaranteed a 5% to 6% profit to AMTD IDEA Group on the hotel business for two years following the deed of variation signing.
(Updates with the stock movement in the headline and last paragraph.)Telix Pharmaceuticals (ASX:TLX) and United Imaging Healthcare North America entered into a memorandum of understanding (MOU) to evaluate a strategic research partnership in the US focused on developing integrated theranostics technologies that combine diagnostics and targeted therapy, Telix said Tuesday after hours.The partnership will evaluate integrating United Imaging's imaging systems, software, connectivity, and artificial intelligence (AI) tools with the company's molecular imaging portfolio and clinical protocols to enhance theranostic workflows.Key focus areas include improving integration of imaging and radiopharmaceutical workflows, standardizing protocol-driven imaging across sites, enhancing treatment planning and patient monitoring, and developing AI-enabled clinical decision support tools.The initial focus will be on TLX101-Px, a positron emission tomography imaging candidate, with opportunities to expand into additional products and markets, as well as pilot programs and protocol optimization efforts.Telix Pharmaceuticals shares fell nearly 3% in recent Wednesday trade.